Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 5:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,188 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: IV isotonic saline Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Single and Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and Repeat Doses of Supratherapeutic Doses of IV GSK2251052 in Healthy Volunteers

NCT01495065
View directory record Official record
Conditions
Community-acquired Infection
Interventions
GSK2251052 750 mg, GSK2251052 1500 mg, GSK2251052 1500 mg BID, GSK2251052 2250 mg, GSK2251052 3000 mg, GSK2251052 0.9% saline
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Sep 16, 2026, 5:29 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Trial of Oxytocin Alone Versus Oxytocin and Propranolol for the Treatment of Abnormal Labor

NCT00315913
View directory record Official record
Conditions
Dysfunctional Labor
Interventions
Propranolol, IV Placebo
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Sep 16, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma

NCT03207243
View directory record Official record
Conditions
Asthma
Interventions
GSK3772847, Placebo, Fluticasone propionate/salmeterol, Fluticasone propionate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
33
States / cities
Birmingham, Alabama • Scottsboro, Alabama • Bakersfield, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 16, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Analgesic Effect of IV Acetaminophen in Tonsillectomies

NCT01691690
View directory record Official record
Conditions
Adenotonsillitis, Tonsillitis
Interventions
Acetaminophen (paracetamol), Normal Saline Flush, Midazolam, Sevoflurane, Nitrous Oxide/Oxygen, Propofol, Morphine, Ondansetron, Dexamethasone
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
2 Years to 9 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Sep 16, 2026, 5:29 PM EDT
Completed Phase 4 Interventional Results available

RCT (Randomized Controlled Trial) of IV Acetaminophen for Post Cesarean Pain Relief

NCT02046382
View directory record Official record
Conditions
Cesarean Section, Pain, Postoperative
Interventions
IV Acetaminophen, Placebo
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Sep 16, 2026, 5:29 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis

NCT00591318
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizoaffective Disorder
Interventions
ceftriaxone, Normal Saline
Drug
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Sep 16, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

NCT03834506
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Pembrolizumab, Docetaxel, Prednisone, Placebo, Dexamethasone
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
28
States / cities
Mobile, Alabama • Fullerton, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 16, 2026, 5:29 PM EDT
Completed Phase 4 Interventional Results available

Effect of Postoperative Single Dose of Ketamine on Pain After Mastectomy

NCT04831736
View directory record Official record
Conditions
Postoperative Pain
Interventions
Ketamine, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Sep 16, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

High-dose Erythropoietin for Asphyxia and Encephalopathy

NCT02811263
View directory record Official record
Conditions
Neonatal Encephalopathy, Birth Asphyxia
Interventions
Normal saline placebo, Erythropoietin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 24 Hours
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
23
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 16, 2026, 5:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Tolerability Study of N6022 in Healthy Subjects

NCT01147406
View directory record Official record
Conditions
Healthy
Interventions
N6022, Placebo
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Sep 16, 2026, 5:29 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Hormonal Mechanisms of Sleep Restriction - Axis Study

NCT03142893
View directory record Official record
Conditions
Sleep Restriction
Interventions
Ketoconazole Pill, Ganirelix, Dexamethasone, Dexamethasone Injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone, Hydrocortisone Injection, Gonadorelin, Corticorelin, Placebo oral capsule, Saline Solution, Saline Solution for Injection
Drug
Lead sponsor
Peter y. Liu
Other
Eligibility
22 Years to 45 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 16, 2026, 5:29 PM EDT
Completed Phase 1 Interventional Results available

A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)

NCT02525471
View directory record Official record
Conditions
ALS
Interventions
RNS60
Drug
Lead sponsor
Sabrina Paganoni, M.D.
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Sep 16, 2026, 5:29 PM EDT
Recruiting Phase 2 Interventional

IVIG for Infection Prevention After CAR-T-Cell Therapy

NCT05952804
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Immune Globulin Infusion (Human), 10% Solution, Anti-CD19 CAR T Cells Preparation, Saline, Biospecimen Collection, Survey Administration, Electronic Health Record Review
Biological · Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Duarte, California • Miami, Florida • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 16, 2026, 5:29 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome

NCT03090620
View directory record Official record
Conditions
Anticholinergics Toxicity
Interventions
Physostigmine, Lorazepam
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years to 17 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 22, 2021 · Synced Sep 16, 2026, 5:29 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT05747924
View directory record Official record
Conditions
FSHD, FSHD1, FSHD2, FMD, FMD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Dystrophies, Facioscapulohumeral Muscular, Dystrophy, Facioscapulohumeral Muscular, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Muscular Dystrophy 2, Facio-Scapulo-Humeral Dystrophy, Atrophy, Facioscapulohumeral, Atrophies, Facioscapulohumeral, Facioscapulohumeral Atrophy, Muscular Dystrophies, Muscular Dystrophy, Facioscapulohumeral, FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Dystrophies, Landouzy-Dejerine, Dystrophy, Landouzy-Dejerine, Landouzy-Dejerine Syndrome, Muscular Dystrophy, Landouzy Dejerine, Progressive Muscular Dystrophy, FSH
Interventions
AOC 1020, Placebo
Drug
Lead sponsor
Avidity Biosciences, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 16, 2026, 5:29 PM EDT
Terminated Phase 3 Interventional Results available

Daptomycin Versus Placebo in Patients With Neutropenia and Fever

NCT01216241
View directory record Official record
Conditions
Febrile Neutropenia
Interventions
Daptomycin, Saline Placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Sep 16, 2026, 5:29 PM EDT
Completed Phase 4 Interventional

Intravenous Ibuprofen for Laparoscopic Bariatric Surgery

NCT01707251
View directory record Official record
Conditions
Obesity
Interventions
Intravenous Ibuprofen, Saline
Drug
Lead sponsor
Jacobi Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2015 · Synced Sep 16, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

NCT00998946
View directory record Official record
Conditions
Lymphoma, B-Cell
Interventions
Pralatrexate, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
11
States / cities
Beverly Hills, California • Post Falls, Idaho • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 16, 2026, 5:29 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Caffeine in Children With Obstructive Sleep Apnea, Dose Response Study

NCT01349205
View directory record Official record
Conditions
Obstructive Sleep Apnea, Enlargement of Tonsil or Adenoid
Interventions
Caffeine and sodium Benzoate 10 mg/kg IV, Caffeine and Sodium Benzoate 20 mg/kg IV, 0.9 NS Saline
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
2 Years to 12 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Sep 16, 2026, 5:29 PM EDT
Completed Phase 1Phase 2 Interventional

Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients

NCT05027269
View directory record Official record
Conditions
DM1, Myotonic Dystrophy 1, Myotonic Dystrophy, Myotonic Dystrophy Type 1 (DM1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Myotonic Muscular Dystrophy
Interventions
AOC 1001, Placebo
Drug
Lead sponsor
Avidity Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 16, 2026, 5:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant

NCT00886262
View directory record Official record
Conditions
Liver Failure
Interventions
Vasopressin, Normal saline placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 16, 2026, 5:29 PM EDT
Recruiting Phase 2 Interventional

The Effects of Tranexamic Acid on Joint Inflammation and Cartilage Health in Anterior Cruciate Ligament Injured Patients

NCT03552705
View directory record Official record
Conditions
Anterior Cruciate Ligament Reconstruction
Interventions
Tranexamic Acid, Placebos
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 30 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 16, 2026, 5:29 PM EDT
Completed Not applicable Interventional Results available

IV Iron for the Anemia of Traumatic Critical Illness

NCT01180894
View directory record Official record
Conditions
Trauma, ICU Anemia
Interventions
Iron sucrose, Placebo
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2018 · Synced Sep 16, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation

NCT03263442
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation, Delirium, Thiamine Deficiency
Interventions
Thiamine, Normal saline
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Sep 16, 2026, 5:29 PM EDT